{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T06:53:11Z","timestamp":1773730391951,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To evaluate the efficacy, safety, and tolerability of soticlestat as adjunctive therapy in pediatric patients with epileptic encephalopathies of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We performed a computerized literature search of MEDLINE, EMBASE, Cochrane Library, Web of Science, Google Scholar, and <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> to identify eligible randomized, placebo-controlled trials (RCTs) until December 2024. We calculated risk ratios (RRs) for efficacy of responder rate, and tolerability profiles in terms of serious adverse event (SAE) and dropout for adverse events as well as the most common side effects. Quality assessment of included RCTs was performed using the Cochrane Collaboration tool.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3 RCTs with 553 patients were included in the current study. Pooled RR for responder was 3.88 (95% CI 1.78\u20138.49, P = 0.001) among patients with DS, and for patients with LGS was 1.56 (95% CI 0.91\u20132.68, P = 0.11). Significantly more patients receiving soticlestat experienced discontinuation than placebo (RR 2.82 1.49\u20135.33, P = 0.001) because of adverse events. No significant difference in SAE was observed between the two treatment groups with RR 0.87 (95% CI 0.55\u20131.39, P = 0.57). Among the most common AE, only constipation occurred more often in the soticlestat group (RR 3.71, 95% CI 1.22\u201311.31, P = 0.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Soticlestat showed significantly higher efficacy in reducing convulsive seizures in patients with DS. Nonetheless, for patients with LGS, the difference between soticlestat and placebo was not statistically significant. The incidence of SAE in patients receiving soticlestat was similar to those receiving placebo; however, substantially more patients allocated to soticlestat discontinued prematurely because of side effects.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1586098","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T05:21:10Z","timestamp":1745385670000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy, safety, and tolerability of soticlestat (TAK-935) as adjunctive therapy in pediatric patients with dravet syndrome and Lennox\u2013Gastaut syndrome: a meta-analysis of 3 randomized controlled trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhang","family":"Lanlan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Nana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Chengzhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/epi4.13075","article-title":"Refining management strategies for Lennox\u2013Gastaut syndrome: updated algorithms and practical approaches","volume":"10","author":"Auvin","year":"2025","journal-title":"Epilepsia Open"},{"key":"B2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3389\/fneur.2017.00505","article-title":"Expert opinion on the management of lennox-gastaut syndrome: treatment algorithms and practical considerations","volume":"8","author":"Cross","year":"2017","journal-title":"Front. Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eplepsyres.2016.05.012","article-title":"Patients with dravet syndrome in the era of stiripentol: a French cohort cross-sectional study","volume":"125","author":"De Liso","year":"2016","journal-title":"Epilepsy Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"109173","DOI":"10.1016\/j.yebeh.2023.109173","article-title":"Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE)","volume":"142","author":"Demarest","year":"2023","journal-title":"Epilepsy Behav."},{"key":"B6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1528-1167.2011.03180.x","article-title":"Conclusions: long-term management of Lennox-Gastaut syndrome: future directions","volume":"52","author":"Douglass","year":"2011","journal-title":"Epilepsia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1111\/epi.17367","article-title":"A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA)","volume":"63","author":"Hahn","year":"2022","journal-title":"Epilepsia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"106646","DOI":"10.1016\/j.eplepsyres.2021.106646","article-title":"A phase 1b\/2a study of soticlestat as adjunctive therapy in participants with developmental and\/or epileptic encephalopathies","volume":"174","author":"Halford","year":"2021","journal-title":"Epilepsy Res."},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"key":"B10","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s40265-023-01936-y","article-title":"Pharmacotherapy for dravet syndrome: a systematic review and network meta-analysis of randomized controlled trials","volume":"83","author":"Lattanzi","year":"2023","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"Epidemiol. Biostat. and Public Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/epi.17509","article-title":"Gain of function SCN1A disease-causing variants: expanding the phenotypic spectrum and functional studies guiding the choice of effective antiseizure medication","volume":"64","author":"Matricardi","year":"2023","journal-title":"Epilepsia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S1474-4422(15)00250-1","article-title":"The genetic landscape of the epileptic encephalopathies of infancy and childhood","volume":"15","author":"McTague","year":"2016","journal-title":"Lancet Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"17081","DOI":"10.1038\/s41598-020-74036-6","article-title":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice","volume":"10","author":"Nishi","year":"2020","journal-title":"Sci. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/epi.17232","article-title":"Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor","volume":"63","author":"Nishi","year":"2022","journal-title":"Epilepsia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/14737175.2024.2323568","article-title":"Diagnosis of Lennox-Gastaut syndrome and strategies for early recognition","volume":"24","author":"Pujar","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1177\/0883073817714394","article-title":"Early diagnosis and treatment of lennox-gastaut syndrome","volume":"32","author":"Resnick","year":"2017","journal-title":"J. Child. Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejpn.2019.12.023","article-title":"Deciphering the concepts behind \u201cEpileptic encephalopathy\u201d and \u201cDevelopmental and epileptic encephalopathy.\u201d","volume":"24","author":"Scheffer","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-024-00546-6","article-title":"Developmental and epileptic encephalopathies","volume":"10","author":"Scheffer","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/epi.17866","article-title":"A systematic literature review on the global epidemiology of Dravet syndrome and Lennox-Gastaut syndrome: prevalence, incidence, diagnosis, and mortality","volume":"65","author":"Sullivan","year":"2024","journal-title":"Epilepsia"},{"key":"B22","unstructured":"Study of soticlestat as an add-on therapy in children, teenagers, and adults with lennox-gastaut syndrome. clinicaltrials.gov\n          \n          \n            \n              Takeda\n              A.\n            \n          \n          \n          2024"},{"key":"B23","unstructured":"Multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of soticlestat as adjunctive therapy in pediatric and young adult subjects with dravet syndrome (DS)\n          \n          \n            \n              Takeda\n              A.\n            \n          \n          \n          2025"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1111\/bcp.14854","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects","volume":"87","author":"Wang","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1111\/bcp.15225","article-title":"Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers","volume":"88","author":"Wang","year":"2022","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1586098\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T05:21:12Z","timestamp":1745385672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1586098\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":25,"alternative-id":["10.3389\/fphar.2025.1586098"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1586098","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"article-number":"1586098"}}